 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || LuLym-T (autologous activated lymphocytes) / Lujia Biomedical
Trial completion date, Trial primary completion date: Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 6, 2025
P2, N=95, Recruiting, Sponsor: Lukas Biomedical Inc.
Trial primary completion date: Jun 2026 --> Dec 2026 | Trial completion date: Aug 2026 --> Jun 2027
- || LuLym-T (autologous activated lymphocytes) / Lujia Biomedical
Trial completion date, Trial primary completion date: Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 5, 2023
P2, N=95, Recruiting, Sponsor: Lukas Biomedical Inc.
Trial primary completion date: Jun 2026 --> Dec 2026 | Trial completion date: Aug 2026 --> Jun 2027 Trial completion date: Dec 2023 --> Aug 2026 | Trial primary completion date: Dec 2023 --> Jun 2026
- | LuLym-T (autologous activated lymphocytes) / Lujia Biomedical
New P2 trial: Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 31, 2022
P2, N=95, Recruiting, Sponsor: Lukas Biomedical Inc.